Abstract
BACKGROUND: The pilot Phase IIb VIKING study suggested that dolutegravir (DTG), an HIV integrase inhibitor (INI), is efficacious in INI-resistant patients at the 50 mg twice-daily dose. However, DTG response was most reduced in subjects carrying resistance-associated mutations at position G140 and Q148. These mutations can cause a 10-20-fold reduced susceptibility to DTG as well as a 96% lower odds of achieving HIV-1 RNA
Original language | English |
---|---|
Pages (from-to) | 69-72 |
Number of pages | 4 |
Journal | Antiviral Therapy |
Volume | 24 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2019 |